IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. - Wikidata - awgldk - TriplyDB

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

http://www.wikidata.org/entity/Q36557573

about

Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery.Extracellular Vesicles As Modulators of Tumor Microenvironment and Disease Progression in Glioma Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.IDH-1R132H mutation status in diffuse glioma patients: implications for classification Classifying lower grade glioma cases according to whole genome gene expression.Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.Quantitative multi-modal MR imaging as a non-invasive prognostic tool for patients with recurrent low-grade glioma.Key rates for the grades and transformation ability of glioma: model simulations and clinical cases.Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community.The Role of ATRX in Glioma Biology.Phase I/II Trial of Vorinostat Combined with Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma: Final Results of Alliance N0874/ABTC 02.ATRX immunostaining predicts IDH and H3F3A status in gliomas.Remote intracranial recurrence of IDH mutant gliomas is associated with TP53 mutations and an 8q gain.Molecular Determinants of Malignant Brain Cancers: From Intracellular Alterations to Invasion Mediated by Extracellular Vesicles.Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status.Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status.MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.Predicting cancer outcomes from histology and genomics using convolutional networks.Mutant ATRX: uncovering a new therapeutic target for glioma.Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling

P2860

Q33711322-9EE757C4-49BF-4655-AEC9-D4660E1BF7E3 Q33876259-A3F41068-A860-463C-83E5-B261A51049A0 Q37086042-2EE41121-FC6A-4219-ABA3-91BA06A7D3E5 Q37298192-664DE90F-8295-44DD-B790-82F1AE2CF91D Q37327761-EA625D8F-D5CF-4A57-9017-411C3A74CE9D Q37687518-ABE93327-7454-43B5-897F-09FA3C85D3D3 Q38931930-00C4ABD0-B6B1-4C3A-9F3A-1E2910D595D9 Q38998271-8045D0C0-E17F-4C14-9839-6B462E5A0219 Q39268920-4A296DCE-BDC7-4ABA-812C-6BFEF508F78B Q40281311-9D0510FB-5462-4F01-B7AA-0C230FC145F2 Q42213417-B90D6BAE-FA29-42B8-8FD5-CB500B967F14 Q42369808-900D956E-AAD6-46CB-AD05-6EE241F617C7 Q42696115-952E4443-81EA-41C6-8AEE-5966BF5E5052 Q42701263-258EE85A-066C-4A82-BAC0-613CC2519482 Q45058556-3575A88B-9377-45EB-B066-A2BD943DBC63 Q47183915-825CE6EC-0B5D-426F-9628-D47FF0C8FA1A Q48035299-2A4D1E30-DF1C-4A88-BBED-99322F0ED84F Q48450133-45D39339-0810-41B8-A823-46069A92E68F Q55280481-6EF21CDF-10F6-4172-B4BB-5071B16CF929 Q55312165-AB90E5ED-7225-4438-971C-E0CC2ED35464 Q55456861-DBEB19D8-E4C2-46B8-A806-8936BFE02E9A Q58776132-3FA95EA2-E747-4D97-B6D6-DCD9BB6BD30F

P2860

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

http://www.wikidata.org/entity/Q36557573

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@ast

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@en

type

label

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@ast

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@en

prefLabel

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@ast

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@en

P1433

Q36557573-10A0D3E1-227B-4707-BECE-B3F06E7619FB

P1476

Q36557573-652C9564-E198-439C-AFF9-808CEE8979DB

P2093

Q36557573-09F33F15-14A0-44DA-A0A3-D9FCAB9D0D9A

Q36557573-0BAF645C-E928-40C2-A8FE-CFB8FCDB2DED

Q36557573-143AA557-2A90-40B7-AC14-D4DF32682200

Q36557573-DE1AF343-2904-45B0-A27D-CBD4C2997802

Q36557573-E2572B4C-D5AC-46E7-BCBD-8FAD5D697060

Q36557573-F107148B-110A-4B22-BEC2-560125B71A2B

P2860

Q36557573-03A8827A-62C2-45EC-8A17-29823547FC13

Q36557573-0AD83474-0A0D-4C2B-BDC5-6084DF0E56F3

Q36557573-1878F856-2E7D-4D72-AD2D-5636F3D526AB

Q36557573-20BB9A0B-8E84-466F-824C-A7A9167AFA3D

Q36557573-2A23F8B3-2F6D-4FC2-925A-D20534E9918C

Q36557573-3072192B-392E-4647-B093-B14D59304EE6

Q36557573-3749666A-529E-4088-BFE1-78BF9F311377

Q36557573-51A3B7A0-C998-4A17-8AE5-D0238C21E1C4

Q36557573-623DD474-16BB-42DB-936A-813C4F4B7393

Q36557573-642ADAA9-6939-4ED2-991A-0BAB549C79DE

P304

Q36557573-B76C1DFC-89C9-4ED4-A803-58062B08EA70

P31

Q36557573-8F925673-01AE-437A-AE91-CCFEAB0BB409

P356

Q36557573-E9FB20A7-16DB-4E3E-B62C-406F6E303AE5

P407

Q36557573-8D4ADD73-11F2-4ED2-8EB4-60CAD44418B0

P433

Q36557573-DF062470-C670-4E1F-975E-26619828A63D

P478

Q36557573-BF48BC95-0CBC-4551-A1FA-403FA4ECF063

P577

Q36557573-87968896-AA9D-416D-AB1B-560CFD8608D7

P698

Q36557573-B048F993-E8E8-4391-8DAC-6595FB49A371

P921

Q36557573-AE01D7F1-B812-4864-BD9F-4D6C5753D661

P932

Q36557573-57B16987-9301-4D95-B8DD-14B37937BB74

P356

ONCOTARGET.4497

P1433

P1476

IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.

@en

P2093

Alissa A Caron

http://www.w3.org/2001/XMLSchema#string

Caterina Giannini

http://www.w3.org/2001/XMLSchema#string

Daniel H Lachance

http://www.w3.org/2001/XMLSchema#string

Heather E Leeper

http://www.w3.org/2001/XMLSchema#string

Paul A Decker

http://www.w3.org/2001/XMLSchema#string

Robert B Jenkins

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

IDH1 and IDH2 mutations in gliomas

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

The 2007 WHO classification of tumours of the central nervous system

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.

Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.

Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician's perspective

IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.

Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma.

P304

30295-30305

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.4497

http://www.w3.org/2001/XMLSchema#string

P407

P433

30

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2015-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26210286

http://www.w3.org/2001/XMLSchema#string

P921

Alþjóðaheilbrigðismálastofnunin

P932

4745799

http://www.w3.org/2001/XMLSchema#string